Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
KA

AMEX · KAPA

Kairos Pharma, Ltd.

Healthcare · Biotechnology

$0.49

Down-$0.02 (-3.03%)

Updated Nov 5, 2026, 8:29 AM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
16.86M
P/E ratio
-3.24
Dividend yield
0.00%
52-week range
$0.22 – $2.16
Volume
43.75K
Avg. volume
529.54K

Price performance · KAPA

KAPA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

KAPA closed at $0.49 after 21 trading sessions, down 43.71% for the selected period.

Last close
$0.49
Period change
-43.71%
Period low
$0.47
Period high
$0.96
Daily close
View OHLC price history
KAPA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$0.5102$0.53$0.4897$0.489743.75K
Nov 3, 2026$0.47$0.505$0.4182$0.505207.47K
Nov 2, 2026$0.541$0.541$0.4735$0.473594.2K
Oct 30, 2026$0.54$0.5499$0.5237$0.5347.41K
Oct 29, 2026$0.5358$0.5763$0.5251$0.5401123.04K
Oct 28, 2026$0.5433$0.5598$0.5231$0.523164.96K
Oct 27, 2026$0.5251$0.5532$0.5251$0.5333.97K
Oct 26, 2026$0.5711$0.58$0.53$0.536166.5K
Oct 23, 2026$0.5437$0.59$0.5302$0.5585112.89K
Oct 22, 2026$0.5852$0.6001$0.5432$0.54484.1K
Oct 21, 2026$0.5662$0.6171$0.565$0.5766165.44K
Oct 20, 2026$0.5575$0.6029$0.5302$0.5837153.53K
Oct 19, 2026$0.6242$0.628$0.5215$0.5701233.83K
Oct 16, 2026$0.6915$0.6915$0.6007$0.6013134.53K
Oct 15, 2026$0.721$0.7315$0.6563$0.6706253.33K
Oct 14, 2026$0.8038$0.8038$0.7108$0.743285.97K
Oct 13, 2026$0.8315$0.8388$0.7834$0.8287156.52K
Oct 12, 2026$0.8145$0.8389$0.74$0.832251.09K
Oct 9, 2026$0.911$1.0039$0.7827$0.8103640.49K
Oct 8, 2026$0.93$1.25$0.915$0.95955.82M
Oct 7, 2026$1.09$1.1399$0.848$0.871.1M

Latest KAPA news

The latest Smart Investors Daily articles mentioning KAPA.

Stock researchCompany · Overview

KAPA research

Overview

Company profile and research snapshot.

Company profile

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
KAPA recent ratings
DateFirmRatingTarget
Nov 19, 2025D. Boral CapitalBuy—
Nov 4, 2025D. Boral CapitalBuy—
Oct 20, 2025D. Boral CapitalBuy—
Oct 7, 2025D. Boral CapitalBuy—
Sep 19, 2025D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma

Toronto, Ontario--(Newsfile Corp. - October 22, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives from around the globe.Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular free financial websites and apps in Canada and for investors globally - with industry leading audience engagement and mobile functionality. Millions of people visit CEO.CA each year to connect with...

Yahoo · Oct 6, 2026

Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer

LOS ANGELES, October 06, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim analysis demonstrated a statistically significant difference in progression-free survival (PFS) between all

Yahoo · Sep 23, 2026

Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA

LOS ANGELES, September 23, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and moderate a discussion in person at the 24th Annual Discovery on Target Drug Discovery Conference. The conference is being held on Sept. 28 to Oct. 1 at the Sheraton Boston Hotel with sessions available on demand on the conference’s website.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By